PubMed · 7024834
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
F Robert. 1981. [Prolactinoma: pathologic aspects].. https://pubmed.ncbi.nlm.nih.gov/7024834/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The high mobility group As (HMGAs) belong to a family of nonhistone nuclear proteins that orchestrate the assembly of nucleoprotein complexes. Through a complex network of protein-DNA and protein-protein interaction, they play important roles in gene transcription, recombination, and chromatin structure. This protein family is involved, through different mechanisms, in both benign and malignant neoplasias. We have recently reported that transgenic mice carrying the Hmga1 or Hmga2 genes under transcriptional control of the cytomegalovirus promoter develop pituitary adenomas secreting prolactin and growth hormone. We have shown that the mechanism of the HMGA2-induced pituitary adenoma is based on the increased E2F1 activity. The expression profile of mouse normal pituitary glands and adenomas induced in HMGA transgenic mice revealed an increased expression of the ccnb2 gene, coding for the cyclin B2 protein, in the neoplastic tissues compared with the normal pituitary gland. Here, we show, by electrophoretic mobility shift assay and chromatin immunoprecipitation, a direct binding of HMGA proteins to the promoter of ccnb2 gene, whereas luciferase assays showed that HMGAs are able to up-regulate ccnb2 promoter activity. Finally, we report an increased CCNB2 expression in human pituitary adenomas of different histotypes that is directly correlated with HMGA1 and HMGA2 expression. Because cyclin B2 is involved in the regulation of the cell cycle, these results taken together indicate that HMGA-induced cyclin B2 overexpression gives an important contribution to experimental and human pituitary tumorigenesis.
BACKGROUND: This study was carried out to clarify the clinico-pathological features of colorectal adenomatous polyps showing negative results on an immunochemical fecal occult blood test. METHODS: Four hundred sixty patients with colorectal adenoma 1.0 cm or larger in diameter served as subjects of this study. They were divided into two groups based on the results of an immunochemical fecal occult blood test with a 3-day method: two hundred twenty four patients with positive results (positive group) and two hundred thirty six patients with negative results (negative group). The above two groups were compared in terms of their individual factors such as lesion site, lesion size, lesion shape, and histological type. RESULTS: In negative group, the frequencies of rectal adenomatous polyps (p<0.01) and colorectal adenomatous polyps 1.0-1.5 cm in size (p<0.001) were higher, and also pedunculated type (p<0.05) were lower than in positive group, but there was no difference in histological type between the two groups. CONCLUSIONS: These findings suggest that immunochemical fecal occult blood testing is relatively inferior for the detection of colorectal adenomatous polyps in rectum, smaller size, and non-pedunculated type.
TSH receptor mutants in the VI transmembrane segment, found in thyroid autonomously functioning adeonomas, have been expressed in differentiated thyroid cells. All mutant receptors constitutively stimulated adenylyl cyclase. The biological activity, measured as cAMP production relative to the wild type receptor, was specific for each mutant in transient and stable transfection assays. Cells expressing these mutants proliferated in the absence of TSH. The rate of growth in the absence of TSH paralleled basal cAMP production for each mutant receptor. Low TSH concentrations stimulated the growth of mutant receptor-expressing cells, and not of the cells expressing the wild type receptor. Also, the entry in the cell cycle and the plating efficiency were markedly stimulated by the expression of the mutant receptors. These data provide a molecular link between the occurrence of TSH receptor mutations and thyroid autonomously functioning adenomas.